Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 μg./l.

Journal of Urology

Volumn 157, Issue 3, 1997, Pages 913-918

  Yu, He ^a   Diamandis, Eleftherios P ^a   Wong, Pui Yuen ^a   Nam, Robert ^a   Trachtenberg, John ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

neoplasm metastasis; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT MONITORING; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; TUMOR VOLUME;

EID: 0031032628     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65082-1     Document Type: Article

References (27)

1. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
2. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen-in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
3. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
4. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
5. Takayama, T. K., Vessella, R. L., Brawer, M. K., Noteboom, J. and Lange, P. H.: The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J. Urol., 150: 374, 1993.
6. Stamey, T. A., Graves, H. C. B., Wehner, N., Ferrari, M. and Freiha, F. S.: Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J. Urol., 149: 787, 1993.
7. Yu, H., Diamandis, E. P., Prestigiacomo, A. F. and Stamey, T. A.: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin. Chem., 41: 430, 1995.
8. Vessella, R. L., Noteboom, J. and Lange, P. H.: Evaluation of the automated Abbott IMx prostate specific antigen (PSA) immunoassay. Clin. Chem., 38: 2044, 1992.
9. Liedtke, R. J., Kroon, G. and Batjer, J. D.: Modified assay of prostate-specific antigen with a detection limit <0.01 microgram/l. Clin. Chem., 39: 2150, 1993.
10. Prestigiacomo, A. F. and Stamey, T. A.: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J. Urol., 152: 1515, 1994.
11. Yu, H. and Diamandis, E. P.: Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin. Chem., 39: 2108, 1993.
12. Ferguson, R. A., Yu, H., Kalyvas, M., Zammit, S. and Diamandis, E. P.: Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin. Chem., 42: 675, 1996.
13. Breslow, N. E. and Day, N. E.: Unconditional logistic regression for large strata. In: Statistical Methods in Cancer Research. The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, World Health Organization, vol. 1, chapt. 6, 1980.
14. Humphrey, P. A., Frazier, H. A., Vollmer, R. T. and Paulson, D. F.: Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer, 71: 1821, 1993.
15. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
16. Epstein, J. I., Carmichael, M., Partin, A. W. and Walsh, P. C.: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J. Urol., 149: 1478, 1993.
17. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N. and Lowe, B. A.: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845, 1993.
18. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol., 149: 516, 1993.
19. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., part 2, 152: 1821, 1994.
20. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., part 2, 152: 1831, 1994.
21. Murphy, G. P., Mettlin, C., Menck, H., Winchester, D. P. and Davidson, A. M.: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J. Urol., part 2, 152: 1817, 1994.
22. Zietman, A. L., Edelstein, R. A., Coen, J. J., Babayan, R. K. and Krane, R. J.: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828, 1994.
23. Partin, A. W., Piantadosi, S., Sanda, M. G., Epstein, J. I., Marshall, F. F., Mohler, J. L., Brendler, C. B., Walsh, P. C. and Simons, J. W.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995.
24. Babaian, R. J., Troncoso, P., Steelhammer, L. C., Lloreta-Trull, J. and Ramirez, E. I.: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J. Urol., 154: 1808, 1995.
25. Diamandis, E. P. and Yu, H.: New biological functions of prostate-specific antigen? J. Clin. Endocr. Metab., 80: 1515 1995.
26. Stamey, T. A.: Lower limits of detection, biochemical detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin. Chem., 42: 849, 1996.
27. Diamandis, E. P., Yu, H. and Melegos, D. N.: Ultrasensitive prostate-specific antigen assays and their clinical application. Clin. Chem., 42: 853, 1996.